The article reports on some very promising developments, but, it has errors.
Here’s a glaring one; .”Antidiabetic drugs currently on the market increase what’s called the basal levels of insulin secretion—it goes up all the time, whether it’s needed or not.”
That’s flat out wrong. It’s true enough that SOME anti-diabetic drugs do just that, but many don’t. Metfromin, for example, works by increasing insulin sensitivity (especially in muscle tissue) while decreasing glucose production in the liver.
What they are talking about is ONE class of diabetes drug, pancreatic stimulators. And even then, they have it wrong; at least one such drug, Starlix (Nateglinide), a D-phenalanaline derivative, works by making the pancreatic production of insulin dependent upon blood glucose levels, rather than just kicking insulin production into overdrive (and thus risking hypoglycenmia).
I chalk up the problems in this article to reporting issue,s not the study itself, which I find very promising. Sounds to me like Dextromethorphan might work in a very similar way to Nateglinide, while being easier and cheaper to use. Nateglinide is expensive, plus not easy to use; you need to take it on an empty stomach at least 20 minutes before (but no more than 60 minutes before) eating in order for it to be fully effective (something even its prescribing info gets wrong – that says take it 0 to 30 minutes before eating, but what they get wrong is that taking it close to eating means you;ll still get a short but significant blood glucose spike). DEX looks to have easier absorption, so should ease the time constraints as well as the cost.
The article reports on some very promising developments, but, it has errors.
Here’s a glaring one;
.”Antidiabetic drugs currently on the market increase what’s called the basal levels of insulin secretion—it goes up all the time, whether it’s needed or not.”
That’s flat out wrong. It’s true enough that SOME anti-diabetic drugs do just that, but many don’t. Metfromin, for example, works by increasing insulin sensitivity (especially in muscle tissue) while decreasing glucose production in the liver.
What they are talking about is ONE class of diabetes drug, pancreatic stimulators. And even then, they have it wrong; at least one such drug, Starlix (Nateglinide), a D-phenalanaline derivative, works by making the pancreatic production of insulin dependent upon blood glucose levels, rather than just kicking insulin production into overdrive (and thus risking hypoglycenmia).
I chalk up the problems in this article to reporting issue,s not the study itself, which I find very promising. Sounds to me like Dextromethorphan might work in a very similar way to Nateglinide, while being easier and cheaper to use. Nateglinide is expensive, plus not easy to use; you need to take it on an empty stomach at least 20 minutes before (but no more than 60 minutes before) eating in order for it to be fully effective (something even its prescribing info gets wrong – that says take it 0 to 30 minutes before eating, but what they get wrong is that taking it close to eating means you;ll still get a short but significant blood glucose spike). DEX looks to have easier absorption, so should ease the time constraints as well as the cost.